Similar articles for PMID: 29136005

Year	Number of Results
1995	1
1999	1
2004	1
2005	1
2006	1
2007	3
2008	6
2010	4
2011	6
2012	5
2013	5
2014	7
2015	11
2016	13
2017	13
2018	6
2019	4
2020	2
2021	3
2022	5
2023	5
2024	0

1

A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer.

Fujishima H, Fumoto S, Shibata T, Nishiki K, Tsukamoto Y, Etoh T, Moriyama M, Shiraishi N, Inomata M. Fujishima H, et al. PLoS One. 2017 Nov 14;12(11):e0188098. doi: 10.1371/journal.pone.0188098. eCollection 2017. PLoS One. 2017. PMID: 29136005 Free PMC article.

2

The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.

Hiyoshi Y, Yoshida N, Watanabe M, Kurashige J, Baba Y, Sakamoto Y, Baba H. Hiyoshi Y, et al. World J Surg. 2017 Feb;41(2):480-486. doi: 10.1007/s00268-016-3649-0. World J Surg. 2017. PMID: 27637603

3

Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.

Akiyama Y, Iwaya T, Endo F, Chiba T, Takahara T, Otsuka K, Nitta H, Koeda K, Mizuno M, Kimura Y, Sasaki A. Akiyama Y, et al. Surg Endosc. 2018 Jan;32(1):391-399. doi: 10.1007/s00464-017-5688-5. Epub 2017 Jun 29. Surg Endosc. 2018. PMID: 28664431

4

Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.

Ojima T, Nakamori M, Nakamura M, Katsuda M, Hayata K, Nakamura Y, Yamaue H. Ojima T, et al. Surg Today. 2017 Jan;47(1):65-73. doi: 10.1007/s00595-016-1338-0. Epub 2016 Apr 29. Surg Today. 2017. PMID: 27130464

5

Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.

Nomura M, Oze I, Abe T, Komori A, Narita Y, Masuishi T, Taniguchi H, Kadowaki S, Ura T, Andoh M, Kawai R, Uemura N, Ishihara M, Tanaka T, Tajika M, Niwa Y, Muro K, Muto M. Nomura M, et al. Cancer Chemother Pharmacol. 2015 Aug;76(2):357-63. doi: 10.1007/s00280-015-2806-8. Epub 2015 Jun 20. Cancer Chemother Pharmacol. 2015. PMID: 26092324

6

Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.

Yamashita K, Katada N, Moriya H, Hosoda K, Mieno H, Katada C, Koizumi W, Hoshi K, Watanabe M. Yamashita K, et al. Gen Thorac Cardiovasc Surg. 2016 Apr;64(4):209-15. doi: 10.1007/s11748-016-0626-3. Epub 2016 Feb 11. Gen Thorac Cardiovasc Surg. 2016. PMID: 26868531 Clinical Trial.

7

Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.

Tanaka Y, Yoshida K, Yamada A, Tanahashi T, Okumura N, Matsuhashi N, Yamaguchi K, Miyazaki T. Tanaka Y, et al. Cancer Chemother Pharmacol. 2016 Jun;77(6):1143-52. doi: 10.1007/s00280-016-2985-y. Epub 2016 Feb 20. Cancer Chemother Pharmacol. 2016. PMID: 26896963 Free PMC article. Clinical Trial.

8

[Current status of neoadjuvant chemotherapy for advanced esophageal cancer].

Tanabe S, Shirakawa Y, Maeda N, Katsube R, Ohara T, Sakurama K, Noma K, Fujiwara T. Tanabe S, et al. Gan To Kagaku Ryoho. 2013 Nov;40(12):1612-4. Gan To Kagaku Ryoho. 2013. PMID: 24393865 Japanese.

9

Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus.

Ui T, Fujii H, Hosoya Y, Nagase M, Mieno MN, Mori M, Zuiki T, Saito S, Kurashina K, Haruta H, Matsumoto S, Niki T, Lefor A, Yasuda Y. Ui T, et al. Dis Esophagus. 2015 Feb-Mar;28(2):180-7. doi: 10.1111/dote.12187. Epub 2014 Feb 17. Dis Esophagus. 2015. PMID: 24529073

10

[Outcome of Patients with Pathological Complete Response after Neoadjuvant Chemotherapy in Advanced Esophageal Cancer].

Hikami S, Shiozaki A, Fujiwara H, Konishi H, Arita T, Kosuga T, Morimura R, Murayama Y, Komatsu S, Ikoma H, Kuriu Y, Nakanishi M, Ichikawa D, Okamoto K, Otsuji E. Hikami S, et al. Gan To Kagaku Ryoho. 2017 Nov;44(12):1796-1798. Gan To Kagaku Ryoho. 2017. PMID: 29394779 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

83 results

Results by year